中信建投：近年肺癌呈现慢病化趋势看好国内企业在肺癌领域突破

智通财经2025-06-17

智通财经APP获悉，中信建投发布研报称，肺癌在全球范围内发病率和死亡率始终排在前列，NSCLC在所有患者中占比接近85%，一直是各大企业的研发重心。肺癌治疗方法持续迭代，患者生存状况逐渐改善。近年来，新型分子开始逐渐崭露头角，包括ADC、双抗等药物分子开始在NSCLC领域展现出色潜力，肺癌呈现慢病化趋势。诸多国内企业积极投入研发创新，优秀临床数据在各类学术会议亮相，看好中国企业在肺癌领域的不断突破...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2544395851?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-17 14:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544395851","market":"fut","top_or_hot":-1,"title":"中信建投：近年肺癌呈现慢病化趋势 看好国内企业在肺癌领域突破","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，中信建投发布研报称，肺癌在全球范围内发病率和死亡率始终排在前列，NSCLC在所有患者中占比接近85%，一直是各大企业的研发重心。肺癌治疗方法持续迭代，患者生存状况逐渐改善。近年来，新型分子开始逐渐崭露头角，包括ADC、双抗等药物分子开始在NSCLC领域展现出色潜力，肺癌呈现慢病化趋势。诸多国内企业积极投入研发创新，优秀临床数据在各类学术会议亮相，看好中国企业在肺癌领域的不断突破...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1306138.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中信建投：近年肺癌呈现慢病化趋势 看好国内企业在肺癌领域突破</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中信建投：近年肺癌呈现慢病化趋势 看好国内企业在肺癌领域突破\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-17 14:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1306138.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中信建投发布研报称，肺癌在全球范围内发病率和死亡率始终排在前列，NSCLC在所有患者中占比接近85%，一直是各大企业的研发重心。肺癌治疗方法持续迭代，患者生存状况逐渐改善。近年来，新型分子开始逐渐崭露头角，包括ADC、双抗等药物分子开始在NSCLC领域展现出色潜力，肺癌呈现慢病化趋势。诸多国内企业积极投入研发创新，优秀临床数据在各类学术会议亮相，看好中国企业在肺癌领域的不断突破...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1306138.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1306138.html","article_id":"2544395851","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544395851","pubTimestamp":1750142316,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，中信建投发布研报称，肺癌在全球范围内发病率和死亡率始终排在前列，NSCLC在所有患者中占比接近85%，一直是各大企业的研发重心。近年来，新型分子开始逐渐崭露头角，包括ADC、双抗等药物分子开始在NSCLC领域展现出色潜力，肺癌呈现慢病化趋势。诸多国内企业积极投入研发创新，优秀临床数据在各类学术会议亮相，看好中国企业在肺癌领域的不断突破。标的方面非小细胞肺癌发病率高，是重要的肿瘤创新药市场。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601066":"中信建投","09926":"康方生物","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK1589":"北水核心资产","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","01801":"信达生物","06990":"科伦博泰生物-B","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK0276":"资本市场","BK1191":"制药","01276":"恒瑞医药","BK1161":"生物科技","BK1593":"医美概念股","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","BK1574":"生物医药B类股","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU1720050803.USD":"安联全方位中国股票基金"},"translate_title":"CITIC Construction Investment: Lung cancer has shown a chronic trend in recent years and is optimistic about domestic companies' breakthroughs in the field of lung cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601066":1,"01801":0.9,"09926":0.9,"01276":0.9,"06990":0.9},"content_text":"智通财经APP获悉，中信建投发布研报称，肺癌在全球范围内发病率和死亡率始终排在前列，NSCLC在所有患者中占比接近85%，一直是各大企业的研发重心。肺癌治疗方法持续迭代，患者生存状况逐渐改善。近年来，新型分子开始逐渐崭露头角，包括ADC、双抗等药物分子开始在NSCLC领域展现出色潜力，肺癌呈现慢病化趋势。诸多国内企业积极投入研发创新，优秀临床数据在各类学术会议亮相，看好中国企业在肺癌领域的不断突破。中信建投主要观点如下：NCCN指南持续更新，新方案陆续加入从24V5版指南至今，诸多获批的新疗法陆续进入指南，对此前指南新增更多选择或者对有所缺失的细分领域进行补全，包括Enhertu用于HER2突变患者的后线治疗等。同时包括阿替利珠以及纳武利尤单抗的皮下剂型陆续进入推荐，为患者提供更好的用药便利性。早期主要通过手术治疗，配合辅助疗法延长生存期近年来的ICI以及靶向疗法已经证实在手术前进行新辅助治疗或者手术后进行辅助治疗，有助于肿瘤的完全切除以及降低癌症复发的风险，越来越多的药物开始从后线向前线进行探索。Dato与度伐的联用展现了ADC在肿瘤控制上的显著作用，围术期pCR率相比对照组获得大幅提升。晚期驱动基因阴性患者前线布局持续增加，后线新疗法展现BIC潜力Non-AGA患者治疗仍以ICI疗法以及化疗为主，其中根据鳞癌或非鳞癌的不同有所区别，鳞癌患者治疗手段相对有限。目前AK112国内已获批单药前线治疗，SKB264联用K药国内外III期临床已经在进行中。后线信达IBI363在此次ASCO数据出色，mOS超过市场预期。晚期AGA领域持续向更多突变类型覆盖存在基因突变患者中EGFR研究最多，奥希替尼已经从后线逐渐突破至新辅助治疗阶段，阿美替尼同样开始向前线推进。艾伯维第一代c-MET ADC顺利获批，二代ABBV-400展现出色初步疗效。Enhertu用于HER2突变NSCLC后线治疗进入NCCN指南，恒瑞SHR-A1811近日也于国内获批HER2突变NSCLC后线治疗。标的方面非小细胞肺癌发病率高，是重要的肿瘤创新药市场。诸多中国企业积极创新，优秀临床数据在各类学术会议涌现。看好国内企业在肺癌领域突破，看好恒瑞医药(01276)、科伦博泰(06990)、信达生物(01801)、康方生物(09926)、新诺威(300765.SZ)、三生制药(01530)、贝达药业(300558.SZ)、艾力斯(688578.SH)等。风险提示审评不及预期风险，行业政策风险，研发不及预期风险，审批不及预期风险，销售不及预期风险，市场竞争加剧风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2544395851","isCrawlerRequest":true}

中信建投：近年肺癌呈现慢病化趋势 看好国内企业在肺癌领域突破

精彩评论

中信建投：近年肺癌呈现慢病化趋势看好国内企业在肺癌领域突破